Over the past decade, neuroproteomics has shed light on the molecular features of schizophrenia by depicting biological processes involved with its establishment, maintenance and treatment. These studies have also pointed to potential biomarkers applicable to diagnosis and medication monitoring. Edited by a leader in the field of neuroproteomics with contributions from subject experts, this new volume will address recent findings and compile evidence from difference perspectives-such as human samples, animal models, pluripotent stem cell-derived in vitro pre-clinical models-and provide findings to inform the development of innovative future treatment strategies.

This volume will be useful for a broad audience of researchers and professionals, including biologists, neurologists, psychiatrists, analytical chemists, and pharmacists, among others.

Provides comprehensive overview on how neuroproteomics helped depicting the molecular features of schizophrenia
Addresses biological processes, treatment strategies, and recent research findings associated to schizophrenia
Addresses current research challenges, future strategies, and clinical applications

Autorentext

Daniel Martins-de-Souza holds a PhD in Biochemistry and Molecular Biology and is an Associate Professor of Biochemistry and Head of Proteomics at the University of Campinas (UNICAMP), in Brazil. Daniel s postdoctoral training was carried out in the Max Planck Institute of Psychiatry in Germany and at the University of Cambridge, in the UK. For two years, Daniel was Principal Investigator in the Dept. of Psychiatry and Psychotherapy of the Ludwig Maximilians University (LMU), just before becoming a Professor. Daniel was elected Affiliated Member of the São Paulo Academy of Sciences in 2019 and Affiliated Member of the Brazilian Academy of Sciences in 2017. He is part of the Editorial Board of seven indexed journals and Associate Editor for npj Schizophrenia. His main expertise is on proteomics and systems biology tools to investigate molecular mechanisms involved in mental disorders.

Inhalt

Postmortem brains: what can proteomics tell us about the sources of schizophrenia?2. What can we learn from animal models to study schizophrenia?3. Modeling schizophrenia in vitro: challenges and insights on studying brain cell4. Schizophrenia outside the brain5. Molecular features triggered by antipsychotic medication in brain cells6. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia7. Molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia8. Metabolomics: A powerful tool to understand the schizophrenia biology9. Modulating specific pathways in vitro to understand the synaptic dysfunction of schizophrenia10. Proteomics and schizophrenia: the evolution of a great partnership